NCT02740712View on ClinicalTrials.gov

Pharmacokinetic Drug-Drug Interaction Study of Rucaparib

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

September 30, 2019

Conditions
Neoplasms
Interventions
DRUG

Caffeine

200 mg (4 x 50mg) Tablet

DRUG

Warfarin

10 mg (2 x 5mg) Tablet

DRUG

Omeprazole

40 mg Tablet

DRUG

Midazolam

5 mg/mL

DRUG

digoxin

.25 mg Tablet

DRUG

Vitamin K

10 mg Tablet

DRUG

Rucaparib

200 \& 300 mg tablet

Trial Locations (3)

05-830

BioVirtus Research Site, Kajetany

60-693

Med Polonia, Poznan

71-730

Zachodniopomorskie Centrum Onkologii Centrum Innowacji, Szczecin

All Listed Sponsors
lead

pharmaand GmbH

INDUSTRY

NCT02740712 - Pharmacokinetic Drug-Drug Interaction Study of Rucaparib | Biotech Hunter | Biotech Hunter